SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Muhammad Ali

PatientMuhammad Ali
Date of birth1972-01-17
IdentifiersMRN HR-BX001-SYN; SSN (made up) 000-01-7724
Document date2026-06-09
AuthorCeleste Moreau, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month Parkinson's disease review after the levodopa increase and speech therapy. [S]

History of Present Illness

Mr. Ali returns three months after his first visit. Since carbidopa-levodopa was increased to one and a half tablets three times a day, taken 30 minutes before meals, he is quicker with buttons and getting out of chairs, and the late-morning slowness has eased. He has had no involuntary movements, no wearing-off before doses, and no lightheadedness on standing, nausea, or sleepiness. He finished the four-week LSVT LOUD speech therapy course two months ago and practices his voice exercises each day; people hear him more easily. He has had six physical therapy sessions and now walks, rides a stationary bicycle, and does balance exercises about 150 minutes a week. He has had no falls. He has had no hallucinations. [S]

ElementDetail
Medicine changeLevodopa 150 mg three times daily before meals for twelve weeks; slowness better
Motor complicationsNo dyskinesia or wearing-off
RehabilitationLSVT LOUD course completed; six physical therapy sessions; home program about 150 minutes a week
FallsNone

Review of Systems

SystemResultFinding
CardiovascularNegativeNo lightheadedness on standing or fainting
GastrointestinalNegativeNo nausea or constipation
NeurologicalPositiveSlowness improved; mild right-hand tremor; no involuntary movements or freezing
PsychiatricNegativeMood good; no hallucinations

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times dailyOne tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m.Oral route2014-10-01 to 2026-03-10completedS
Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before mealsOne and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before mealsOral route2026-03-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-09Body height191cmS
2026-06-09Body weight101.5kgS
2026-06-09Body mass index (BMI) [Ratio]27.8kg/m2S
2026-06-09Systolic blood pressure124mm[Hg]S
2026-06-09Diastolic blood pressure76mm[Hg]S
2026-06-09Heart rate72/minS
2026-06-09Respiratory rate14/minS
2026-06-09Body temperature36.7CelS
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 2026-06-09; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and engaged; voice noticeably louder in conversation
CardiovascularRegular rhythm at 72 per minute. Blood pressure 126/78 mmHg supine and 116/76 mmHg after 3 minutes standing, a 10 mmHg fall in systolic pressure, without symptoms; no orthostatic hypotension
NeurologicalOn state: MDS-UPDRS Part III 24, down from 30; Hoehn and Yahr stage 2.5; milder bradykinesia and rigidity; mild right-hand rest tremor; no dyskinesia
GaitLonger steps and better arm swing; recovers after two steps on the pull test; Timed Up and Go 11 seconds

Problems

ProblemClinical statusVerificationCodeProvenance
Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuationsactiveconfirmed G20.A1S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic.
Hypokinetic dysarthria with soft speech due to Parkinson's diseaseactiveconfirmed R47.1S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationMDS-UPDRS Parts III and IV and Hoehn and Yahr stageEvery visitCompleted todayPart III 24, down from 30; Hoehn and Yahr 2.5; Part IV: no dyskinesia, wearing-off, or on-off
ExaminationOrthostatic blood pressure, supine and after 3 minutes standingEvery visit while on dopaminergic treatmentCompleted today126/78 mmHg supine and 116/76 mmHg at 3 minutes standing after the dose increase; no orthostatic hypotension
Medication safetyDopaminergic regimen review for wearing-off, dyskinesia, and on-offEvery visitCompleted todayGood response to levodopa 150 mg three times daily with no motor complications; no change
Medication safetyAvoidance of dopamine-blocking drugsEvery visitCompleted todayNo dopamine-blocking drugs
Medication safetyMedication side effects and adherenceEvery visitCompleted todayNo nausea, sleepiness, or missed doses; doses now taken before meals
ExaminationFall query and fall-risk assessment (Timed Up and Go, pull test)Every visitCompleted todayNo falls; Timed Up and Go 11 seconds, improved from 13; recovers after two steps on the pull test
SurveyPsychotic symptoms (hallucinations, delusions)Every visitCompleted todayNone
SurveyImpulse-control screen (QUIP-RS)Every visit; mandatory on a dopamine agonistDeferredNot asked at this visit, a deviation from the every-visit item. He is not on a dopamine agonist, and the screen at the six-month review was negative, so no impulse-control problem was missed. Corrective action: the screen is added to the standing visit checklist
Self-managementExercise counseling: aerobic, resistance, and balance, at least 150 minutes a weekEvery visitCompleted todayAbout 150 minutes a week of walking, cycling, and balance exercises
Self-managementAdvance care planning and goals of careAt diagnosis and at least yearlyDuePlanned for the preventive visit in the autumn
ExaminationDiagnosis review against the MDS clinical diagnostic criteriaYearlyUp to dateConfirmed by neurology three months ago
SurveyCognitive screen (MoCA)At least yearlyUp to dateMoCA 27 of 30 four months ago
SurveyDepression, anxiety, and apathy (PHQ-9)At least yearlyUp to datePHQ-9 3 four months ago; mood good today
SurveySleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legsAt least yearlyUp to dateNo dream enactment or daytime sleepiness
SurveyAutonomic symptoms: constipation, urinary, sexual, sweating, droolingAt least yearlyUp to dateNo constipation or urinary symptoms
SurveySwallowing screen (EAT-10)At least yearlyUp to dateEAT-10 2 four months ago; no choking or coughing with meals since
ExaminationSpeech and voice loudnessYearly; speech therapy for speech changeCompleted todayLSVT LOUD course completed; louder speech today
ReferralPhysical, occupational, and speech therapyAt diagnosis, then reassessed yearlyCompleted todaySpeech therapy completed; physical therapy in progress, moving to a home program
LaboratoryGenetic testing with counselingOnce, offered to every person with Parkinson's diseaseDueOffered three months ago; decision at the yearly neurology review
ExaminationDental and oral examinationEvery 6 monthsDueNot yet arranged; due by six months
ExaminationDriving safetyYearly or with a motor or cognitive changeUp to dateMotor function better; review yearly
Self-managementVaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap)Yearly, per the CDC scheduleDueTo be reviewed at the preventive visit in the autumn
LaboratoryRoutine laboratory monitoringNot required for Parkinson's disease surveillanceNot indicatedThe CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit
ImagingBrain MRIIf atypical parkinsonism features appearNot indicatedNo atypical features; examination unchanged apart from the improvement
ImagingPolysomnography for REM sleep behavior disorderIf REM sleep behavior disorder treatment is consideredNot indicatedNo dream enactment
Medication safetyAGS Beers Criteria medication reviewYearly from age 65Not indicatedHe is 54
ExaminationDeep brain stimulation programming reviewEvery 6 to 12 months after implantationNot indicatedNo deep brain stimulator

Goal progress:

Guideline basis: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026)

Follow-up: Six-month Parkinson's disease review in three months. Next scheduled visit 2026-09-08: six-month Parkinson's disease review. [S]